Cerebrolysin

Cerebrolysin is a parenterally administered neuropeptide preparation produced by standardized enzymatic breakdown of purified porcine (pig) brain proteins. It consists of approximately 80 percent low-molecular-weight peptides and 20 percent free amino acids, with all components below 10 kDa to enable blood-brain barrier penetration. The peptide mixture is designed to mimic endogenous neurotrophic factors including BDNF, NGF, CNTF, and GDNF. It is administered as intravenous infusion or intramuscular injection.

The compound was first developed in 1949 by Austrian professor Gerhart Harrer and received regulatory approval in Austria in 1954. It has later been registered in more than 45 countries across Europe, Asia, and Latin America for ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease. The compound is manufactured by Ever Neuro Pharma (formerly EBEWE Pharma) in Austria.

The Stroke Evidence: CARS and CARS-2

The CARS (Cerebrolysin and Recovery After Stroke) trials are the largest randomized controlled trials of Cerebrolysin in acute ischemic stroke recovery. CARS-1 and CARS-2 were identical prospective, randomized, double-blind, placebo-controlled multicenter trials. Treatment with 30 mL Cerebrolysin daily for 3 weeks was started 24 to 72 hours after stroke onset in combination with standardized rehabilitation. The trials together enrolled approximately 400 patients.

The 2017 meta-analysis of CARS-1 and CARS-2 (Bornstein et al.) reported significant improvements in motor recovery during early rehabilitation in patients treated with Cerebrolysin compared with placebo. The effects were larger in patients with more severe baseline motor deficits, suggesting the compound is more useful in moderate-to-severe stroke than in milder presentations.

Earlier trials had produced mixed results. The 2012 Cochrane review concluded that the available evidence was insufficient to evaluate Cerebrolysin for stroke. A large 2012 trial (Heiss et al., Stroke) cast doubt on usefulness in stroke except possibly in severe cases. The CARS data partially addressed these concerns by focusing on patients with more severe deficits.

The Dementia Evidence

The 2011 Alvarez trial combined Cerebrolysin (10 mL) with donepezil (10 mg) in a randomized double-blind design and reported that the combination produced the best cognitive scores at every study visit. The 2019 Cochrane review (Cui et al.) on vascular dementia concluded that Cerebrolysin appeared to provide benefits on cognitive function and global function, though the quality of evidence was variable.

Cerebrolysin's proposed mechanism centers on neurotrophic factor mimicry. The peptide components are believed to act on multiple cellular targets that overlap with endogenous neurotrophic factors.

BDNF, NGF, CNTF, GDNF mimicry. The peptide mixture appears to engage the signaling pathways that endogenous neurotrophic factors normally activate. These pathways support neuronal survival, dendritic branching, synaptic plasticity, and resistance to ischemic damage.

Neuroprotection in ischemia. In animal models of stroke, Cerebrolysin reduces infarct size, decreases excitotoxicity, and supports endogenous repair mechanisms.

Neurogenesis stimulation. Animal data documents that Cerebrolysin increases neurogenesis in the subventricular zone and dentate gyrus.

Amyloid-beta processing modulation. Some research has reported effects on amyloid-beta accumulation and clearance.

Regulatory status

International approval. Cerebrolysin is approved in more than 45 countries including Austria (1954), Germany, Russia, China, South Korea, Romania, Mexico, and multiple Eastern European and Latin American jurisdictions. Approved indications vary by country but commonly include ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease.

United States. Cerebrolysin has no FDA approval. The compound has not been formally submitted for FDA evaluation as a New Drug Application.

Compounding status. Cerebrolysin is not on the FDA Category 2 bulks list as of May 2026, partly because it is a complex biological preparation rather than a defined bulk peptide.

WADA status. Cerebrolysin is not on the WADA Prohibited List.

Approved Label Doses by Indication

Cerebrolysin label dosing varies by indication across the 45+ approval countries. The Austrian label (Ever Neuro Pharma) and most EU labels share similar protocols.

Acute ischemic stroke (CARS protocol): 30 mL daily as slow intravenous infusion for 21 consecutive days, started 24 to 72 hours after stroke onset. Administration in 100 to 250 mL of saline or 5 percent dextrose over 60 to 90 minutes. This is the dosing used in CARS-1 and CARS-2 trials and reflects the strongest evidence base for the compound.

Traumatic brain injury: 30 to 50 mL daily IV for 10 to 20 days, depending on severity. Higher doses are reserved for severe TBI in inpatient settings. Pediatric protocols use weight-adjusted dosing under specialist supervision.

Vascular dementia and Alzheimer's disease: 10 to 30 mL daily as IV infusion or IM injection for 5-day-per-week courses of 4 weeks. Treatment courses are typically repeated 2 to 4 times per year. The Alvarez 2011 combination trial used 10 mL daily.

Mild cognitive impairment: Lower-end dosing of 10 to 20 mL daily for 4-week courses, repeated 2 times per year.

Administration Technique

Intravenous infusion is the preferred route for higher doses (above 10 mL). Cerebrolysin is added to 100 to 250 mL of compatible IV solution (0.9 percent saline, 5 percent dextrose, or Ringer's solution) and infused over 60 to 90 minutes. Rapid infusion increases the risk of flushing, sweating, and transient hypertension.

Intramuscular injection is used for lower doses (up to 5 mL per injection site, with larger total doses split across multiple sites). The IM route is more common in outpatient maintenance protocols and is the typical route for the 5 to 10 mL doses used in dementia.

Subcutaneous administration is occasionally used in some Eastern European practice settings but is not the labeled route in most jurisdictions.

Pharmacokinetics

Cerebrolysin is a multi-component preparation, so a single half-life value does not apply. Different peptide components and free amino acids have different absorption, distribution, and elimination profiles. Free amino acids reach peak plasma concentration within 30 to 60 minutes after IV infusion. Peptide components have longer apparent half-lives that vary by molecular weight and structure.

The blood-brain barrier penetration that motivates the compound's CNS use depends on the low molecular weight of the components (all below 10 kDa). Different peptides cross with different efficiency, and the cumulative CNS exposure is what drives the neurotrophic effect rather than any single component.

Clearance is through standard amino acid metabolism and peptide proteolysis. No dose adjustment is required for renal or hepatic impairment in the published clinical protocols, although patients with severe organ dysfunction are typically excluded from trial populations.

Treatment Cycles

The Cerebrolysin dosing paradigm is cycle-based rather than continuous. Standard practice across approved indications is to administer the compound in defined treatment courses (typically 10 to 21 days) followed by treatment-free intervals (typically 2 to 3 months), then a repeat course. The rationale is partly cost (the compound is administered parenterally in supervised settings) and partly the observation in trial data that benefits accumulate across courses rather than requiring continuous administration.

For chronic dementia maintenance, 2 to 4 treatment courses per year are typical. For acute stroke or TBI, a single 21-day course is followed by reassessment.

Pediatric Dosing

Pediatric protocols use weight-adjusted dosing of approximately 0.1 to 0.2 mL/kg/day, with maximum single-dose limits varying by age. Pediatric use is concentrated in TBI, perinatal hypoxic-ischemic encephalopathy, and developmental disorders. Pediatric administration requires specialist neurology supervision.

The cumulative safety record across more than 70 years of clinical use in more than 45 countries is generally favorable. The compound is broadly tolerated in stroke, TBI, and dementia populations.

Local injection-site reactions are the most common adverse events with intramuscular administration. Erythema, mild pain, and transient swelling. Generally self-limited.

Mild flushing and warmth during intravenous infusion. Resolves with slower infusion rate.

Allergic reactions in rare cases. The compound is derived from porcine brain proteins, so theoretical risks include allergic responses, though these have been infrequent in practice. Patients with known allergies to porcine products are excluded.

Transient elevations in liver enzymes have been reported at low rates.

No serious systemic toxicity has emerged from the cumulative post-marketing dataset. The compound has been used in elderly populations, post-stroke patients, and pediatric TBI without flagging dose-limiting toxicity.

Cerebrolysin occupies a unique position because it is a preparation rather than a defined molecule.

Cerebrolysin vs Citicoline. Both are used internationally for neuroprotection in stroke and neurodegeneration. Citicoline is an endogenous nucleotide (cytidine-5'-diphosphocholine) with a defined molecular structure, available oral and parenteral routes. The ICTUS trial in 2,298 patients reported no significant benefit of citicoline on the primary endpoint in acute stroke. Cerebrolysin's stroke evidence is mixed but includes the positive CARS meta-analysis.

Cerebrolysin vs Piracetam. Piracetam is a racetam nootropic with separate mechanism. Cochrane reviews of piracetam for stroke and dementia concluded insufficient evidence of benefit. Cerebrolysin has more positive trial data in stroke recovery.

Cerebrolysin vs Semax. Both are used in Russian neurology for stroke. Semax is a defined seven-amino-acid peptide. Cerebrolysin is a multi-component porcine preparation. The two are sometimes used together but have different mechanistic profiles.

Cerebrolysin vs Donepezil. The Alvarez combination trial reported additive effects of Cerebrolysin plus donepezil in Alzheimer's disease, suggesting complementary rather than competing mechanisms.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.